Table 4. Tyrosine kinase expression pattern in melanoma tissues and corresponding cell lines.
| Patient #02 | Patient #05 | Patient #16 | Patient #18 | |
|---|---|---|---|---|
| Female | Male | Female | Male | |
| 51 years | 62 years | 41 years | 52 years | |
| Tissue | ||||
| Origin | Subcutaneous | Subcutaneous | Lymph node | Lymph node |
| Immunohistochemistry | ||||
| CD117/c-kit | ++ | +++ | + | ++ |
| PDGF-Rα | + | − | + | + |
| PDGF-Rβ | + | + | − | − |
| Cell line | ||||
| Name | Ma-Mel-46 | Ma-Mel-52 | Ma-Mel-54a | Ma-Mel-59a |
| Immunohistochemistry | ||||
| CD117/c-kit | + | − | ++ | − |
| PDGF-Rα | − | − | ++ | ++ |
| PDGF-Rβ | ++ | − | + | − |
| RT–PCR | ||||
| CD117/c-kit | + | + | + | (+) |
| PDGF-Rα | + | + | + | + |
| PDGF-Rβ | + | + | + | + |
| Patient's clinical outcome | ||||
| Overall survival (days) | 88 | 7 | 20 | 74 |
Expression of tyrosine kinases was measured in melanoma tissue samples and corresponding cell lines as described in Patients and Methods. The patients are numbered according to the time point of inclusion into the study.